Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information.
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
-- Roche to acquire InterMune for $74.00 per share --
BASEL, Switzerland, Aug.
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review
INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ --
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses
BOTHELL, Wash. and
Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis
New CE mark in the European Union extends application to routine pathology including primary diagnosis with human tissue specimens